Related Experiment Videos
The effect of pravastatin in patients with primary hyperlipidaemia
M Mafauzy1, M Mokhtar, W B Wan Mohamad
1Department of Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan.
Insights
Pravastatin effectively lowers high cholesterol levels in patients with primary hyperlipidaemia. This study shows significant reductions in total cholesterol, LDL-cholesterol, and triglycerides, alongside an increase in HDL-cholesterol.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Primary hyperlipidaemia is a condition characterized by elevated levels of lipids in the blood.
- Effective management of hyperlipidaemia is crucial for reducing cardiovascular disease risk.
Purpose of the Study:
- To evaluate the efficacy of pravastatin in lowering lipid levels in patients with primary hyperlipidaemia.
- To determine the optimal dosage of pravastatin based on initial cholesterol levels.
Main Methods:
- A study involving 34 subjects with primary hyperlipidaemia.
- Initial treatment with low-fat diet, followed by pravastatin 10 mg nocte for subjects with total cholesterol >= 6.2 mmol/l.
- Dose escalation to 20 mg nocte for non-responders, with lipid levels monitored over 12 weeks.
Main Results:
- Pravastatin significantly reduced total cholesterol, LDL-cholesterol, and triglycerides.
- Mean reductions observed: triglyceride (15.7%), total cholesterol (18.1%), LDL-cholesterol (26.3%).
- Significant increase in HDL-cholesterol (19.4%) and indication that initial cholesterol levels predict optimal pravastatin dosage.
Conclusions:
- Pravastatin is an effective lipid-lowering agent for primary hyperlipidaemia.
- The optimal dose of pravastatin appears to be dependent on the patient's baseline total cholesterol levels.
- Further research may be warranted to establish definitive dosing guidelines.
Abstract:
Thirty-four (34) subjects with primary hyperlipidaemia were enrolled for this study. After low fat dietary therapy for 6 weeks, subjects' whose serum total cholesterol fell to below 6.2 mmol/l (11 subjects) were excluded from the study and those whose serum total cholesterol were 6.2 mmol/l or more (23 subjects) were started on pravastatin 10 mg nocte. After 8 weeks of treatment, there was a significant decrease in the mean total cholesterol and LDL-cholesterol. However 13 of the subjects still had serum total cholesterol 6.2 mmol/l or more and their pravastatin dose was increased to 20 mg nocte. After 12 weeks, there was a significant reduction in triglyceride, total cholesterol and LDL-cholesterol. There was also a significant increase in HDL-cholesterol. The triglyceride fell by a mean of 15.7%, total cholesterol by a mean of 18.1% and LDL-cholesterol by a mean of 26.3%. HDL-cholesterol on the other hand, increased by 19.4%. The subjects whose total cholesterol fell below 6.2 mmol/l at week 8 had significantly lower total cholesterol to begin with than those whose total cholesterol failed to do so and hence were commenced on 20 mg pravastatin. This suggests that the optimum dose of the drug is dependent on the initial level of total cholesterol. We conclude that pravastatin is effective as a lipid lowering agent.